Amendment to the Specification:

At the indicated page and line numbers, please replace the existing sections or paragraphs, as the case may be, with the ones set forth below.

(Page 4, lines 3 through 21)

In accordance with one aspect of the present invention, there is provided a cancer-specific radiolabeled conjugate of the formula:



(I)

wherein B* represents ~~5'-substituted~~ uracil substituted with a radionuclide; R represents H, OH, or O-L-DHT, L being a cleavable bifunctional linking moiety and DHT is 4-dihydrotestosterone, which is bound through its hydroxyl substituent to said linking moiety; and R' represents a phospho group or a substituted phospho group having the formula $-PO(OR_a)(OR_b)$, $-PO(OR_a)(ODHT)$ or $-PO(ODHT)_2$, R_a and R_b being the same or different and representing H or lower alkyl and DHT is as previously defined, with the proviso that at least one of the R and R' substituents comprises a DHT moiety.

(Page 7, line 34 through page 9, line 2)

Specific examples of conjugates within the scope of this invention are the following:



,



,



,



,



, and



.

Synthetic routes for the preparation of these conjugates are exemplified hereinbelow.